Close Menu

Castle Biosciences

The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.

The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.

The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.

The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.

Survey results reflect strong penetration of Castle Biosciences' uveal melanoma test among specialists as the company plans a future focus on more prevalent diseases.

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Castle Biosciences today said that it raised $11.8 million in a Series E financing round.

Originally published May 6. NEW YORK (GenomeWeb) – Castle Biosciences presented data from two validation studies involving its DecisionDx - Mesothelioma molecular test at the American Association for Thoracic Surgery annual meeting.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.